Angiogenesis Induced in the Elderly by Hyperbaric Oxygen Therapy

Aging Clinical Trial

— ANGIOHBOT  

Official title:

Changes in Blood Flow and Angiogenesis Induced in the Elderly by Hyperbaric Oxygen Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02790541
• Other study ID #: 0172-15-ASF
• Status: Completed
• Phase: N/A
• Start date: December 2016
• Est. completion date: January 2020

Study information

• Verified date: January 2020
• Source: Assaf-Harofeh Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Recent studies show preliminary evidence of HBOT therapeutic effects on angiogenesis, increased tissue blood flow and oxygenation correlated with tissue function.

Our primary hypothesis is that HBOT will have beneficial effects on the above mentioned organs associated with aging-related malfunctions due to restored mitochondrial function, mobilization of stem cells and induction of angiogenesis.

Description:

The paradigm The accumulation of damage to molecules, cells and tissues over a lifetime that contributes to aging eventually leads to frailty and malfunction. The past decade has seen fundamental advances in our understanding of the aging process and raised optimism that interventions to slow ageing may be on the horizon. The aging process is linked to energy deficit due to tissue hypoxia and mitochondria dysfunction.

• Mitochondria dysfunction- Mitochondria are the primary generator of energy by means of ATP synthesis and their dysfunction leads to cellular function decline and degenerative changes. In addition, mitochondria dysfunction in stem cells decreases the capabilities for tissue regeneration.

• Tissue hypoxia- Atherosclerosis is a chronic inflammatory response that damages arterial blood vessels. It begins in childhood and progresses throughout life. A vicious cycle occurs as mitochondrial dysfunction accelerates atherosclerosis and the waning of microvasculature, resulting in decrease blood supply and ensuing relative tissue hypoxia. The decrease oxygen supply to the mitochondria further exacerbates mitochondrial dysfunction.

Hyperbaric oxygen can increase the partial pressure of dissolved (non-hemoglobin-bound) oxygen 20-30 fold and produce two main effects. First, it can eliminate the relative tissue hypoxia induced by atherosclerosis. Second, because mitochondria function is directly influenced by the partial pressure of dissolved oxygen, hyperbaric oxygen can amend mitochondrial dysfunction. Thus, the investigators suggest hyperbaric oxygen as a novel method for breaking the vicious cycle of degeneration and perhaps even for reversing the aging process.

The study is designed as a prospective crossover study aiming to evaluate the therapeutic effects of HBOT on the Brain, Cardiovascular and Immune system, Skin, Erectile (sexual functions), liver and Kidneys, of aging population.

After signing an informed consent form, patients will be invited for baseline evaluations. All patients would be evaluated 3 times - at baseline, after 3 months of follow up, and after additional 3 months of HBOT protocol. The evaluation will include cognitive assessment, questionnaires, MRI scans, blood tests and skin photograph and biopsy. In addition, blood tests will be drawn before and after the 20th, 40th and the 60th sessions for stem cells and mitochondria tests.

Patients will receive 60 daily sessions, 5 days/week, 90 minutes each with 5 minutes air break every 30 minutes, 100% oxygen at 2 ATA.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: January 2020
• Est. primary completion date: January 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Age= 65 years

• Capability to sign informed consent.

• No cardiac or cerebrovascular ischemia previous events one year prior to inclusion.

Exclusion Criteria:

• Previous treatment with HBOT for any other reason during the last 3 months prior to inclusion.

• Any history of malignancy during the last year prior to inclusion.

• Severe cognitive decline (MMSA<17)

• Severe chronic renal failure (GFR <30)

• Uncontrolled diabetes mellitus (HbA1C>8, fasting glucose>200)

• Immunosuppressant from any reason

• Contraindications to perform MRI: claustrophobia, allergy to gadolinium, foreign bodies, pacemaker, etc.

• Active Smoking.

• Pulmonary diseases such as severe emphysema, moderate-severe obstructive disease.

• Medical conditions deemed by the investigator to make the patient ineligible for protocol investigations.

Related Conditions & MeSH terms

• Aging

Intervention

Device:
• Hyperbaric Oxygen Therapy
60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 3 months.

Locations

Country	Name	City	State
Israel	Asaf Harofeh Medical Center	Zerifin

Sponsors (1)

Lead Sponsor	Collaborator
Assaf-Harofeh Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline of Angiogenesis in brain MRI at 3 and 6 months	imaging will be performed for evaluation of brain changes and angiogenesis processs using MRI perfusion (DSC)	at baseline, 3 and 6 months
Primary	Change from baseline of general cognitive functions index at 3 and 6 months	Patients' cognitive functions will be assessed by Neurotrax computerized cognitive tests to generate the general cognitive index	at baseline, 3 and 6 months
Primary	Change from baseline of exercise VO2 MAX at 3 and 6 months	Using a standard exercise test which includes gas analysis, the change in VO2 maxs will be assessed 3 and 6 months compared to baseline	at baseline, 3 and 6 months
Secondary	Change in number of circulating stem cells (CD34) at 3 and 6 months	Blood samples will be drawn for measurements of CD34 stem cells number analyzed by FACS.	at baseline, 3 and 6 months
Secondary	Change from baseline of proteinuria at 3 and 6 months	24-hours urine will be collected from all patients for evaluation of proteinuria	at baseline, 3 and 6 months
Secondary	Change from baseline of Methacetin breath test at 3 and 6 months	All patients will undergo Methacetin breath test. Voltile CO2 levels will be compared to evaluate changes in liver function.	at baseline, 3 and 6 months
Secondary	Change from baseline in bone density at 3 and 6 months	All patients will undergo Dual-energy X-ray absorptiometry to evaluate the change bone density changes	at baseline, 3 and 6 months
Secondary	Change from baseline in quality of life measured by SF-36 form at 3 and 6 months	All patients will fill SF-36 questionnaire to evaluate the change in quality of life	at baseline, 3 and 6 months